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BY R ANDERSON, N SHAH
More sensitive visual acuity test for  
age-related macular degeneration
A
ge-related macular degeneration 
(AMD) is the leading cause of 
blindness in the developed world. 
Primarily associated with ageing, 
genetic factors and lifestyle choices such 
as smoking also play a contributory role. 
Patients with early AMD, characterised by 
the development of small- and medium-
sized drusen or retinal pigment epithelial 
abnormalities, and those with intermediate 
AMD, characterised by medium and large 
drusen and / or geographic atrophy not 
involving the centre of the fovea, are often 
asymptomatic. It is usually the two forms 
of late AMD; geographic atrophy involving 
the fovea and neovascular AMD, that are 
most strongly associated with symptomatic 
vision changes. These symptoms consist 
of a reduction or loss of central vision with 
or without distortion which commonly 
manifests as a difficulty in reading or 
recognising faces. In recent times, the 
management of wet or neovascular 
AMD has been revolutionised with the 
introduction of intravitreal injections 
of anti-vascular endothelial growth 
factor (anti-VEGF) such as ranibizumab 
(Lucentis) or bevacizumab (Avastin) and 
more recently aflibercept (Eylea), resulting 
in the delayed progression of visual loss 
if not improvement of vision. Although 
the processes in non-neovascular AMD 
are not fully understood, a number of 
different treatments are being investigated 
which either act to prevent the loss of 
photoreceptors and retinal pigment 
epithelial cells (e.g. visual cycle inhibitors) or 
to suppress inflammation (e.g. complement 
inhibitors). The Age Related Eye Disease 
Study (AREDS) has demonstrated beneficial 
effects in terms of reducing the risk of 
progression with oral supplementation of 
antioxidant vitamins and minerals in those 
with intermediate AMD and those with 
late AMD in one eye. Assuming that any 
future therapies will be more effective if 
administered early in the disease process, 
it becomes all the more important to 
possess a test that is sensitive to the earliest 
changes in AMD, while at the same time 
displaying good repeatability in order to 
better monitor its progression.
Why the need for a new visual 
acuity test?
The conventional test of visual function 
in AMD is high contrast visual acuity (VA) 
measurement. Traditionally this was done 
using the Snellen chart, which consists 
of rows of black-on-white high-contrast 
letters with an unequal number of letters 
on each line and an unequal change in letter 
size between lines. As more treatments 
became available for AMD, the necessity 
of being able to accurately detect and 
monitor for a change in visual function 
became more significant and testing using 
charts employing a Logarithm of Minimum 
Angle of Resolution (logMAR) design has 
become a requirement. The Early Treatment 
Diabetic Retinopathy Study (ETDRS) chart 
using single letter scoring is considered 
to be the current gold standard. Every 
row is comprised of five letters, sized and 
spaced such that each letter contributes 
a score of 0.02 log units. A logMAR visual 
acuity score of 0.00 means that the eye can 
resolve detail that subtends 1/60 degrees 
of visual angle (i.e. one minute of arc), 
equivalent in size to a 6/6 letter on the 
Snellen scale. Visual acuity of 1.00 logMAR 
indicates that the eye is resolving detail 
subtending 10 minutes of arc, equivalent 
in size to a 6/60 letter (Figure 1). The 
problem with measuring visual function 
using these charts in AMD is that VA often 
remains normal, even in advanced disease 
until the fovea is observably affected. 
Conventional letters are ideal as targets 
to measure errors of refraction since they 
are particularly vulnerable to the effects 
of spurious resolution caused by optical 
defocus as a result of phase reversals 
within their rich spatial frequency spectra, 
resulting in the letter quickly becoming 
harder to resolve with decreasing angular 
size. However, these letters appear to be 
much less sensitive in indicating visual loss 
as a result of neural processes in early and 
intermediate AMD with studies reporting a 
decrease in VA of only two or fewer letters 
in patients displaying early AMD lesions. It 
seems that only a weak relationship exists 
between the severity of retinal changes and 
VA, influenced by the location and extent 
of the lesion in addition to the pathology 
stage. Traditional VA tests provide an 
indication of the highest spatial frequency 
that can be resolved by the visual system at 
high contrast. Other tests of visual function 
in AMD have been investigated including 
reading speed, photostress recovery, foveal 
flicker sensitivity and microperimetry. 
Low contrast VA measurements can 
also provide additional information by 
reporting the highest spatial frequency 
that can be resolved at low contrast. These 
tests, however, have demonstrated poor 
repeatability, possibly owing to the acute 
angle at which a stimulus modulating 
in spatial frequency strikes the contrast 
sensitivity function in the low contrast part 
of the curve. It is important to be able to 
assess visual function that is specifically 
sensitive to the neural changes in AMD 
whilst also displaying good repeatability. 
Additionally, the test must be easily 
understood by patients and be simply and 
quickly administrable in routine clinical 
settings.
In an attempt to investigate and address 
this problem, our team at Moorfields has 
designed a pseudo high-pass letter VA 
chart which is more sensitive to the early 
signs of AMD. Addressing a high priority 
for research as identified by the 2013 Sight 
Loss and Vision Priority Setting Partnership, 
the project was funded by Fight for Sight 
and the Special Trustees of Moorfields Eye 
Hospital NHS Foundation Trust.  The results 
have been published in the British Journal of 
Ophthalmology [1]. 
Figure 1: Visual acuity in Snellen notation and its conversion 
to spatial frequency. (Kalloniatis M, Luu C. Visual acuity. 
Webvision. Reproduced with kind permission of the authors. 
Full article available here: http://webvision.med.utah.edu/
book/part-viii-gabac-receptors/visual-acuity)  
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What is the difference between the 
new chart and existing ones?
Howland et al. [2] described letter stimuli in 
which large inter-letter legibility differences 
are effectively overcome by removing the 
low spatial frequencies. These high-pass 
filtered letters, each made up of a black 
core and white surround are presented on 
a grey background, the luminance of which 
is equivalent to the mean luminance of 
the letter. As the letter reduces in size to 
the threshold acuity level, the high spatial 
frequencies beyond the resolution limit 
of the retina are filtered by the optics of 
the eye. The result is that under foveal 
viewing conditions, the detection and 
recognition thresholds coincide such that 
when a letter can no longer be recognised, 
it cannot be detected either, hence their 
alternative name as vanishing optotypes. 
Conventional letters do not behave in the 
same way since their luminance difference 
to the background results in separate 
values for the detection and recognition 
thresholds. Under peripheral viewing 
conditions, however, the two thresholds 
for vanishing optotypes also separate 
and previous studies have confirmed that 
resolution of these stimuli is determined by 
neural sampling density rather than optics 
[3,4]. Employing these stimuli instead of 
conventional black-on-white stimuli in a 
VA test may allow for better sensitivity to 
the neural changes associated with AMD. 
Furthermore, initial studies with these 
letters demonstrated that VA measured 
with these letters displayed lower variability 
[5,6] whilst also demonstrating a greater 
robustness to the effects of optical defocus 
in normal subjects [7]. In order to investigate 
their usefulness in a clinical acuity test 
several preliminary studies of the five-year 
project led to the eventual design of the 
Moorfields Acuity Chart (MAC). This chart 
is based on the gold standard layout of 
the ETDRS chart with five letters per line 
in 0.10 logMAR steps, but replacing the 
conventional letter design with the high-
pass filtered letters (Figure 2).
The experimental protocol
VA measurements were compared for 38 
normal subjects and 80 patients with a 
range of VA owing to AMD. The mean VA 
was measured to be 0.00 logMAR (range 
-0.12 to 0.26 logMAR) and 0.45 logMAR 
(range -0.02 to 1.20 logMAR) for the normal 
subjects and AMD patients respectively. 
Each participant underwent baseline 
refraction at 4m and ocular examination 
to exclude any other significant pathology. 
VA measurements were then taken on 
two different conventional black-on-white 
logMAR charts (C1 and C2) and two different 
MAC charts (MAC 1 and MAC 2).  Bland-
Altman statistics and linear regression were 
used to analyse the data. The difference 
in VA measurements attained between 
the two different chart types gives an 
indication of the bias. The difference in 
VA measurements between the same 
chart types gives an indication as to the 
repeatability of the measurement with that 
chart type with test-retest variability (TRV) 
expressed as the 95% limits of agreement.  
What the results suggest
Unsurprisingly, conventional letter chart 
measurements gave ‘better’ VA scores than 
the MAC chart in normal subjects since the 
low spatial frequency information remains 
available for letter identification. This 
difference was around 1.5 lines.  However, 
for AMD participants with good VA levels 
similar to those of normal subjects, the 
‘deficit’ in MAC chart VA was considerably 
larger, with a mean difference between 
the two chart types (C1 and MAC 1) of 
approximately 4.5 lines. For AMD subjects 
at the poorer acuity end, the difference was 
approximately 2.5 lines. This suggests that 
the MAC chart is able to detect functional 
loss owing to AMD at levels where 
conventional acuity remains relatively 
unaffected, particularly in its earlier stages. 
However, whilst the MAC may result in a 
stronger disease signal, this is of little value 
if it is lost in the test variability. TRV was 
found to be similar for both charts in both 
the normal and AMD groups, ranging from 
+/-0.09 to +/-0.12 logMAR. 
Why should the MAC display 
higher sensitivity to visual loss in 
AMD?
Simulations suggest that, as photoreceptors 
‘drop out’ as AMD develops, resolution 
of the high-pass filtered letters on 
the MAC chart suffers more from the 
effects of neural under-sampling than 
it does for conventional letters. For 
conventional letters, a larger proportion of 
photoreceptors must become dysfunctional 
before the loss causes resolution to fail 
compared to vanishing optotypes in AMD. 
As the fovea becomes more involved, 
recognition of both charts suffers in a more 
equal fashion, explaining why the difference 
Figure 2: Image of the Moorfields Acuity Chart (MAC).
With the projected number 
of people with AMD 
worldwide predicted to be 
196 million by 2020 and 
with an increasing number 
of treatments becoming 
available, the ability 
to detect AMD earlier is 
absolutely vital
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in acuity loss between the two charts 
becomes smaller.  In other words, with 
conventional letters which contain a 
range of spatial frequencies, the visual 
system is able to shift to using the lower 
spatial frequencies and these are more 
robust to undersampling. With the MAC 
chart, acuity is affected sooner with 
undersampling since the only available 
higher spatial frequencies can no longer 
be resolved and the letter quickly 
becomes unidentifiable.
Patient benefit 
With the projected number of people 
with AMD worldwide predicted to 
be 196 million by 2020 [8] and with 
an increasing number of treatments 
becoming available, the ability to detect 
AMD earlier is absolutely vital. Whilst 
other tests of visual function in AMD 
exist, high contrast VA measurements 
remain the only internationally accepted 
endpoint for clinical trials. Results with 
the MAC test thus far suggest that it 
may be an effective tool with which to 
achieve this, whilst also being simple 
to administer routinely in a clinic 
environment and easily understood 
by patients. The chart is produced 
commercially under licence by Peter 
Allen and Associates and we are 
preparing for a larger clinical trial in AMD 
patients in order to be able to build up a 
normative database of VA results with 
the MAC chart at different stages of the 
AMD disease process. Whilst the MAC 
chart will not replace the normal chart 
for refraction, its seeming sensitivity to 
neural damage means that a patient’s 
comparative results between the 
conventional and MAC charts may yield 
invaluable insights and could become 
a commonly used tool in detecting and 
monitoring AMD.  These results will 
also be very important and potentially 
translational to other disease processes 
such as diabetic retinopathy and further 
studies will be needed to investigate this. 
A recent exploratory study incorporating 
these vanishing optotypes in a letter 
recognition task in perimetry testing 
suggests these may also be able to offer 
a suitable patient friendly test to obtain 
a sampling-limited measure of ganglion 
cell density in glaucoma patients.
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- Current gold standard tests of visual function in AMD are logMAR based, high 
contrast, black-on-white visual acuity measurements.
- These tests demonstrate poor sensitivity to the early changes associated with 
AMD, often only being significantly affected once the fovea is involved.
- The Moorfields Acuity Chart is constructed using high-pass filtered letters in 
which the low spatial frequency information is effectively filtered out.
- Visual acuity measurements taken using this chart appear to be more sensitive 
to functional loss in AMD compared with conventional letter charts, with similar 
test-retest variability measures.
- With increasing treatment options becoming available for AMD, earlier detection 
is vital and the Moorfields Acuity Chart may make this achievable.
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